Resverlogix Announces Voting Results From the 2023 Meeting of Shareholders
Resverlogix Announces Voting Results From the 2023 Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - June 20, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta.
加拿大阿尔伯塔省卡尔加里-(Newsfile Corp.-2023年6月20日)-Resverlogix Corp.(多伦多证券交易所股票代码：RVX)(以下简称“Resverlogix”，或“公司”)今天在阿尔伯塔省卡尔加里召开年度股东大会(以下简称“股东大会”)。
During business proceedings at the Meeting, shareholders elected five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:
在会议的业务程序中，股东选举了五(5)名董事会成员，直至下一次年度会议。个别董事代表出席会议的股份表决结果如下：
| Votes For | Votes Withheld | Percent For | Percent Withheld | |
| Donald J. McCaffrey | 122,884,287 | 11,547,550 | 91.41% | 8.59% |
| Shawn Lu | 123,340,266 | 11,091,571 | 91.75% | 8.25% |
| Kelly McNeill | 127,204,762 | 7,227,075 | 94.62% | 5.38% |
| Siu Lun (Dicky) To | 127,856,904 | 6,574,933 | 95.11% | 4.89% |
| Kenneth Zuerblis | 129,096,743 | 5,335,094 | 96.03% | 3.97% |
| 投票赞成 | 扣留的选票 | 百分比为 | 扣缴百分比 | |
| 唐纳德·J·麦卡弗里 | 122,884,287 | 11,547,550 | 91.41% | 8.59% |
| 肖恩·Lu | 123,340,266 | 11091571 | 91.75% | 8.25% |
| 凯利·麦克尼尔 | 127,204,762 | 7,227,075 | 94.62% | 5.38% |
| 萧伦(迪奇)至 | 127,856,904 | 6574,933 | 95.11% | 4.89% |
| 肯尼斯·祖尔布利斯 | 129,096,743 | 5,335,094 | 96.03% | 3.97% |
Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated May 10, 2023 (the "Information Circular"). The Information Circular is available on SEDAR at , and on the Resverlogix website at .
Resverlogix股东批准了日期为2023年5月10日的会议通知和管理层信息通告(“信息通告”)中概述的所有决议。《信息通报》可在SEDAR和Resverlogix网站上查阅。
A webcast archive of the executive presentation portion of the Meeting will be available HERE.
会议执行演示文稿部分的网络直播档案将在此处提供。
About Resverlogix
关于Resverlogix
Founded in 2001, Resverlogix is a Calgary-based, late-stage, biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Resverlogix成立于2001年，是一家总部设在卡尔加里的晚期生物技术公司，是表观遗传学领域的世界领先者，目标是为慢性病患者开发一流的治疗方法。
Our new class of epigenetic therapies are designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.
我们的新型表观遗传疗法旨在调节致病基因的表达。我们的目标是通过将因心血管疾病等严重疾病而改变的生物功能恢复到更健康的状态来改善患者的生活。
The Company's clinical program is focused on evaluating our lead candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and post COVID-19 conditions.
该公司的临床计划侧重于评估我们治疗心血管疾病和相关合并症以及新冠肺炎后遗症的主要候选药物阿帕贝酮。
Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us:
Resverlogix普通股在多伦多证券交易所(多伦多证券交易所市场代码：RVX)交易。跟我们来：
- Twitter: @Resverlogix_RVX
- LinkedIn:
- 推特：@Resverlogix_rvx
- LinkedIn：
For further information please contact:
欲了解更多信息，请联系：
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
投资者关系
电子邮件：ir@resverlogix.com
电话：403-254-9252
To view the source version of this press release, please visit
要查看本新闻稿的源版本，请访问